Life Sciences companies are currently impacted by various trends that increase the complexity of their business, particularly in the supply chain area. The differentiation of supply chains might be a way out of the complexity trap. But what does the pharmaceutical industry think about this? Are differentiated supply chains seen as a suitable approach to master complexity?
The current 7th PHARMA Management Radar survey explores
- which industry trends are the main drivers for an increasing complexity
- whether and to what extent Life Sciences companies are already applying differentiation strategies to address complexity
- in which areas and how comprehensively these strategies are applied or planned
- what the most effective segmentation criteria and procedures for differentiated supply chains are.
In addition, the survey examines the general business climate in the Life Sciences industry.
